secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2026-08-10T11:05:20+00:00
Accession:  0001193125-26-341206
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q2 2026 revenue up 46% to $218.4M; AUVELITY Alzheimer's launch underway
------------------------------------------------------------------------------

- Total net product revenue $218.4M, +46% YoY; AUVELITY sales $180.3M (+51% YoY), SUNOSI $35.8M (+20%), SYMBRAVO $2.3M (+461%).
- Net loss $51.3M ($0.99/share) vs $48.0M loss ($0.97) in Q2 2025; SG&A up to $208.1M from $130.3M on launch activities.
- AUVELITY launched for Alzheimer's disease agitation in June 2026; new-to-brand Rx +126% in patients ≥65 in first 8 weeks.
- NDA for AXS-12 (cataplexy in narcolepsy) accepted by FDA; PDUFA target action date May 1, 2027.
- Cash $319.9M at June 30, 2026; guidance says sufficient to fund operations into cash flow positivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/0001193125-26-341206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer